Pontifax Management 4 G.P. (2015) Ltd.
- SEC CIK
- 0001726334
In the past year, 1 open-market sale filing worth $85.0M and no purchases.
Current role at each company
- KROS Keros Therapeutics, Inc.10% Owneras of Oct 17, 2025
- LBRX LB Pharmaceuticals Inc10% Owneras of Sep 16, 2025
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $85.0M
- 1 filing
- Net
- −$85.0M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Pontifax Management 4 G.P. (2015) Ltd. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
KROS Keros Therapeutics, Inc.
10% Owner1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 17, 2025 (view filing)5:53 PM ET | Oct 15 | 2 days | Kariv Tomer and 7 othersDirector, 10% Owner | SSaleCommon Stock, $0.0001 par value per share | −4.79M | $17.75 | −$85.0M | −100.0%0 after | 4 lots |
LBRX LB Pharmaceuticals Inc
10% Owner1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 16, 2025 (view filing) | Sep 12 | 4 days | Pontifax Management 4 G.P. (2015) Ltd.10% Owner | PPurchase | +1.00M | $15.00 | +$15.0M | +242.9%1.41M after | Duplicate filing |